Imbruvica (ibrutinib) / Royalty, Generic mfg., AbbVie, J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

250 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Imbruvica (ibrutinib) / AbbVie, J&J
NCT02455297: Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Terminated
2a
4
US
Copanlisib (BAY80-6946)
Bayer
Lymphoma, Mantle-Cell
04/16
08/16
NCT02351037: Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

Terminated
2a
36
US
Ibrutinib, Cohort 1, Ibrutinib + LD-AraC, Cohort 2, Ibrutinib+Azacitidine, Cohort 3
Pharmacyclics LLC.
Acute Myeloid Leukemia (AML)
04/17
04/17
PS-CLL-002, NCT04754035: Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Active, not recruiting
2a
31
Europe
Venetoclax, Imbruvica Oral Product
Paolo Ghia
Chronic Lymphocytic Leukemia
07/18
09/25
NCT02874404: TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed
2a
13
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202, RP5264, TGR-1202
University of Nebraska, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
07/19
07/19
PCYC-1104-CA, NCT01236391 / 2010-022939-11: Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Checkmark For mantle cell lymphoma at EHA 2013
Jun 2013 - Jun 2013: For mantle cell lymphoma at EHA 2013
Checkmark PCYC-1104 trial for relapsed or refractory mantle cell lymphoma at EHA 2013
May 2013 - May 2013: PCYC-1104 trial for relapsed or refractory mantle cell lymphoma at EHA 2013
Checkmark ASH 2012
More
Completed
2
115
US, Europe
PCI-32765
Pharmacyclics LLC., Janssen Pharmaceuticals
Mantle Cell Lymphoma
01/14
01/14
RESONATE-17, NCT01744691 / 2012-004476-19: A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Checkmark BSH 2015
Apr 2015 - Apr 2015: BSH 2015
Checkmark RESONATE-17 trial in relapsed or refractory CLL/SLL with 17p deletion (ASH 2014)
Nov 2014 - Nov 2014: RESONATE-17 trial in relapsed or refractory CLL/SLL with 17p deletion (ASH 2014)
Checkmark For relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with 17p deletion (RESONATE™-17)
More
Completed
2
145
US, Canada, Europe, RoW
Ibrutinib
Pharmacyclics LLC., Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia With 17p Deletion, Small Lymphocytic Lymphoma With 17p Deletion
06/14
04/16
12-H-0035, NCT01500733: PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Checkmark AACR 2016
Mar 2016 - Mar 2016: AACR 2016
Checkmark For CLL/SLL
Nov 2013 - Nov 2013: For CLL/SLL
Checkmark ASH 2013
More
Active, not recruiting
2
86
US
PCI 32765
National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Leukemia, Lymphocytyc, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma)
06/14
09/34
NCT01325701: Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Checkmark For relapsed/refractory DLBCL at EHA 2013
Jun 2013 - Jun 2013: For relapsed/refractory DLBCL at EHA 2013
Checkmark ASH 2012
Jan 2013 - Jan 2013: ASH 2012
Completed
2
78
US
ibrutinib, PCI-32765, Imbruvica
Pharmacyclics LLC.
Diffuse Large Cell B-lymphoma
10/14
10/14
PCI-32765MCL2001, NCT01599949 / 2012-000711-88: A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

Completed
2
120
US, Europe, RoW
Ibrutinib
Janssen Research & Development, LLC, Pharmacyclics LLC.
Mantle Cell Lymphoma
05/15
05/15
NCT02129062: Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Terminated
2
3
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Laboratory Biomarker Analysis
National Cancer Institute (NCI), M.D. Anderson Cancer Center
Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1, Recurrent Adult Acute Lymphoblastic Leukemia
11/15
11/15
NCT02013128: Ublituximab + Ibrutinib in Select B-cell Malignancies

Checkmark From ublituximab + ibrutinib combination trial in relapsed/refractory mantle cell lymphoma at ASH 2015
Dec 2015 - Dec 2015: From ublituximab + ibrutinib combination trial in relapsed/refractory mantle cell lymphoma at ASH 2015
Checkmark From ublituximab + ibrutinib combination trial for CLL at ICML 2015
Jun 2015 - Jun 2015: From ublituximab + ibrutinib combination trial for CLL at ICML 2015
Checkmark Combination study with ibrutinib for CLL
More
Completed
2
66
US
Ublituximab, Ibrutinib, Ibrutinib (IMBRUVICA)
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
12/15
12/15
2015-005273-20: Multicenter phase II single arm open-label study on the feasibility, safety and efficacy of combination of CHOP-21 supplemented with Obinutuzumab and Ibrutinib in untreated young high risk Diffuse Large B-cell Lymphoma (DLBCL) patients. Studio multicentrico di fase II a braccio singolo sulla fattibilit¿, sicurezza ed efficacia della combinazione CHOP-21 con Obinutuzumab e Ibrutinib come terapia di prima linea in pazienti giovani ad alto rischio affetti da linfoma a grandi cellule B.

Not yet recruiting
2
90
Europe
Imbruvica, Ibrutinib, Concentrate for solution for infusion, Capsule, hard, GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (90 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche, Janssen - Cilag
Diffuse Large B-Cell lymphoma (DLBCL) Linfoma a grandi cellule B (DLBCL), Diffuse Large B-Cell lymphoma Linfoma a grandi cellule B, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
DAWN, NCT01779791 / 2012-004097-26: A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma

Checkmark Data presentation for refractory follicular lymphoma
Dec 2016 - Dec 2016: Data presentation for refractory follicular lymphoma
Completed
2
110
US, Europe, RoW
PCI-32765 (Ibrutinib), IMBRUVICA
Janssen Research & Development, LLC, Pharmacyclics LLC.
Lymphoma
05/16
05/16
2012-003608-11: Assessing how the drug ibrutinib works in Chronic Lymphocytic Leukaeamia.

Ongoing
2
40
Europe
Ibrutinib, PCI-32765, Capsule, hard
University of Birmingham, LLR, Pharmacyclics
Chronic Lymphocytic leukaemia, A form of leukaemia in which there are an excess of mature but poorly functioning lymphocyte cells in the blood., Diseases [C] - Cancer [C04]
 
 
2015-005525-39: The iMYC study to assess the effectiveness and safety of ibrutinib in patients with advanced oesophagogastric cancer with c-MYC and HER2 gene amplification

Ongoing
2
17
Europe
Ibrutinib, JNJ-54179060, Capsule, Ibrutinib
The Royal Marsden NHS Foundation Trust
Her2 or cMYC positive advanced oesophagogastric carcinomas, Cancers arising from either the oesophagus or stomach that display abnormalities of 2 specific genes which are implicated in cancer development: either the Her2 gene, the cMYC gene or both., Diseases [C] - Cancer [C04]
 
 
NCT01849263: Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Active, not recruiting
2
41
Canada, US, RoW
Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
06/16
03/26
PCYC-1121-CA, NCT01980628 / 2013-003561-34: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma

Checkmark In R/R marginal zone lymphoma
Feb 2017 - Feb 2017: In R/R marginal zone lymphoma
Checkmark Approved for relapsed/refractory marginal zone lymphoma
Jan 2017 - Jan 2017: Approved for relapsed/refractory marginal zone lymphoma
Checkmark for Marginal Zone Lymphoma (MZL)
More
Completed
2
63
Europe, US
ibrutinib, PCI-32765
Pharmacyclics LLC., Janssen Research & Development, LLC
Marginal Zone Lymphoma, B-cell Lymphoma
07/16
10/17
NCT01589302: PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Checkmark P1/2 data-EHA
May 2012 - May 2012: P1/2 data-EHA
Active, not recruiting
2
154
US
ibrutinib, Bruton's tyrosine kinase inhibitor PCI-32765, BTK inhibitor PCI-32765, PCI-32765, Correlative laboratory samples, laboratory biomarker anyalysis, quality of life assessment
Kami Maddocks, MD
Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory/Relapsed Chronic Lymphocytic Leukemia
07/16
12/25
iLOC, NCT02542514: Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Completed
2
52
Europe
Ibrutinib
The Lymphoma Academic Research Organisation
Primary Central Nervous Lymphoma, Intraocular Lymphoma
08/16
12/21
CLL2-BIG, NCT02345863 / 2014-000569-35: Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients

Completed
2
66
Europe
Bendamustine, GA101, Obinutuzumab, Ibrutinib
German CLL Study Group, Hoffmann-La Roche, Janssen-Cilag Ltd.
Chronic Lymphocytic Leucemia
08/16
03/19
NCT01614821: Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Checkmark In previously treated patients with WM
May 2018 - May 2018: In previously treated patients with WM
Checkmark
Apr 2015 - Apr 2015: 
Checkmark For relapsed/refractory Waldenstrom’s macroglobulinemia
More
Completed
2
63
US
PCI-32765, ibrutinib
Dana-Farber Cancer Institute
Waldenstrom's Macroglobulinemia
09/16
09/18
2015-005454-35: An early phase study using a response based combination therapy of rituxumab and ibrutinib in patients with post-transplant lymphoproliferative disorder (PTLD)

Ongoing
2
60
Europe
Imbruvica, Rituximab, Cyclophosphamide, Doxorubicin, Prednisolone, Vincristine, Capsule, hard, Infusion, Oral solution, Imbruvica, MabThera, Myocet, Prednisolone
University of Birmingham, Bloodwise, Janssen
Post-transplant lymphoproliferative disorder, Post-transplant lymphoproliferative disorder, Diseases [C] - Cancer [C04]
 
 
NCT02989532: Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Active, not recruiting
2
41
US, Canada, RoW
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis
Mayo Clinic, National Cancer Institute (NCI)
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Follicular Lymphoma
10/16
 
NCT02169180: Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Completed
2
16
Japan
Ibrutinib, IMBRUVICA, PCI-32765, JNJ-54179060
Janssen Pharmaceutical K.K.
Lymphoma, Mantle-cell
11/16
12/16
NCT02415608: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Terminated
2
4
US
Ibrutinib, Imbruvica, PCI-32765, BTK Inhibitor PCI-32765, CRA-032765
Jason Robert Gotlib, National Cancer Institute (NCI)
Aggressive Systemic Mastocytosis, Mast Cell Leukemia, Systemic Mastocytosis
11/16
06/17
FIL-GALILEO, NCT02670317 / 2015-005273-20: Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.

Terminated
2
1
Europe
Obinutuzumab, GA101, Ibrutinib, Imbruvica, CHOP, Cyclophosphamide, doxorubicin, vincristine, and prednisone, Hydroxydaunomycin, Oncovin
Fondazione Italiana Linfomi ONLUS, Roche, Janssen - Cilag
Lymphoma, B-Cell
02/17
02/17
NCT01981512: Study of Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia

Recruiting
2
18
US
Ibrutinib
National Cancer Institute (NCI)
Hairy Cell Leukemia
05/17
05/17
ICLL-07, NCT02666898: Phase II Trial GA101 Inbrutinib B CLL

Completed
2
135
Europe
GA101, Obinutuzumab, Ibrutinib, Imbruvica, Cyclophosphamide, Endoxan, Fludarabine, Fludara
French Innovative Leukemia Organisation, Roche Pharma AG, Janssen-Cilag Ltd.
Leukemia, Lymphocytic, Chronic, B-Cell
05/17
09/23
2016-004707-32: Clinical trial with Ibrutinib and Venetoclax for patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Studio Clinico con Ibrutinib e Venetoclax per pazienti con Leucemia Linfatica Cronica Recidivante o Refrattaria

Ongoing
2
31
Europe
VENETOCLAX, [ABT-199], Film-coated tablet
OSPEDALE SAN RAFFAELE, Abbvie
Relapsed or Refractory Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica Recidivante o Refrattaria, Chronic Lymphocytic Leukemia relapsed or refractory to previous treatments Leucemia Linfatica Cronica ricaduta o non responsiva ai trattamenti precedenti, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2016-002599-29: A trial evaluating treatment with ibrutinib plus venetoclax in patients with creatinine clearance ≥ 30 ml/min who have relapsed or refractory chronic lymphocytic leukemia (RR-CLL)

Ongoing
2
230
Europe
venetoclax 10 mg, venetoclax 50 mg, venetoclax 100 mg, ibrutinib, Tablet, Capsule, hard, Venclyxto, Imbruvica
HOVON Foundation, AbbVie, Janssen
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
CLL2-BIO, NCT02689141 / 2014-000590-39: Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients

Completed
2
66
Europe
Bendamustine, Ofatumumab, Ibrutinib
German CLL Study Group, Gilead Sciences, Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia
07/17
02/20
NCT01980654: Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Checkmark Imbruvica + rituximab for the 1L follicular lymphoma at ASH 2015
Dec 2015 - Dec 2015: Imbruvica + rituximab for the 1L follicular lymphoma at ASH 2015
Completed
2
80
US
Ibrutinib, PCI-32765, rituximab, Rituxan
Pharmacyclics LLC.
Follicular Lymphoma, B-cell Lymphoma, Non-Hodgkin's Lymphoma
11/17
11/17
NCT02272686: Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma

Terminated
2
1
US
Ibrutinib, PCI-32765, Imbruvica
M.D. Anderson Cancer Center, Pharmacyclics LLC.
Lymphoma
12/17
12/17
NCI9922, NCT02581930: Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active, not recruiting
2
18
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Melanoma, Recurrent Cutaneous Melanoma, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/18
03/26
NCT03427398: Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

Active, not recruiting
2
18
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Pharmacogenomic Study, PHARMACOGENOMIC, Pharmacological Study
National Cancer Institute (NCI)
Metastatic Melanoma, Recurrent Melanoma of the Skin, Stage IV Cutaneous Melanoma AJCC v6 and v7
02/18
 
2014-005341-44: Tumor profiling

Completed
2
64
Europe
Vargatef, EMEA/H/C/002569, Tablet, Powder for infusion, Concentrate for solution for infusion, Powder for solution for injection/infusion, Powder for injection, Solution for infusion, , Capsule, Suspension for injection, Powder for concentrate for solution for injection/infusion, Concentrate for solution for injection/infusion, Capsule, soft, Concentrate for solution for injection, Concentrate and solvent for solution for injection/infusion, Powder for solution for infusion, Implant, Kit for radiopharmaceutical preparation, Capsule, hard, Solution for injection/infusion, Powder and solvent for solution for injection, Solution for injection in pre-filled syringe, Concentrate and solvent for solution for infusion, Powder for solution for injection, Powder and solvent for solution for injection in pre-filled syringe, Concentrate and solvent for concentrate for solution for infusion, Solution for injection, Zytiga, Kadcyla, Giotrif, Arimidex, Trisenox, Erwinase, Inlyta, Vidaza, Levact, Avastin, Bleomycin, Velcade, Bosulif, Adcetris, Jevtana, Xeloda, Carboplatin, Erbitux, Leukeran, Cisplatin, Evoltra, Xalkori, Endoxan powder and capsule, Alexan and Cytarabin, Tafinlar, DepoCyte, Dacarbazin Lipomed, Sprycel, Daunoblastin, Dacogen, Firmagon, Docetaxel and Taxotere, Myocet, Caelyx, Epirubicin and Farmorubicin, Xtandi, Halaven, Tarceva, Etoposid concentrate and Vepesid capsule, Afinitor, Exemestan and Aromasin, Faslodex, Neoflubin, 5-Fluorouracil "Ebewe", Iressa, Gemzar, Zoladex, Zevalin, Imbruvica, Holoxan, Glivec, IntronA, Yervoy, Irinotecan, Tyverb, Revlimid, Femara, Calciumfolinat, Eligard Depot and Trenantone, Puri-Nethol and Xaluprine suspension, Methotrexat "Lederle" and Ebetrexat, Methotrexat and Ebetrexat, Metoject PEN and Ebetrexat and Methotrexat, Mitomycin C, Tasigna, Gazyvaro, Arzerra, Eloxatin and Ebeoxal and Oxaliplatin, Abraxane and Ebetaxel and Paclitaxel, Vectibix, Votrient, PegIntron and ViraferonPeg, PegIntron and ViraferonPeg injector, Alimta, Perjeta, Imnovid, Iclusig, Fortecortin and Aprednislon, Stivarga, MabThera, Jakavi, Nexavar, Sutent, Nolvadex, Temozolomide SUN, Torisel, Thalidomide, Hycamitin, Fareston, Mekinist, Herceptin and Kadcyla, Zelboraf, Velbe, Oncovin and Vincristin, Navelbine and Eberelbin, Zaltrap, Vargatef
Medical University of Graz, Medical University of Graz
Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established.A progression of the tumor is confirmed due to the last evidence-based drug therapy. Due to circulating tumor-DNA (ctDNA) in a blood sample and/or tissue sample of metastasis, a molecular-biologic tumor profiling is performed and an adapted tumor-specific drug therapy is selected., Patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug treatment is established., Diseases [C] - Cancer [C04]
 
 
2017-001099-49: therapy with ibrutinib for patients with Chronic lymphocytic leukemia with subclonal TP53 aberrations terapia con Ibrutinib per pazienti affetti da leucemia linfatica cronica che presentano alterazioni subclonali di TP53

Ongoing
2
185
Europe
ibrutinib, [PCI-32765], Capsule, hard
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
Chronic Lymphocytic Leukemia (CLL) leucemia linfatica cronica (LLC), Chronic Lymphocytic Leukemia never treated leucemia linfatica cronica mai trattata, Diseases [C] - Cancer [C04]
 
 
GELLC-7, NCT03280160 / 2016-004937-26: Protocol Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab

Active, not recruiting
2
84
Europe
Ibrutinib 140 MG Oral Capsule [Imbruvica], Ofatumumab
PETHEMA Foundation
Chronic Lymphocytic Leukemia
07/18
09/22
NCT01478581: Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

Completed
2
92
US
PCI-32765, Ibrutinib, Dexamethasone
Pharmacyclics LLC.
Multiple Myeloma
08/18
08/18
NCT01520519: Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients

Checkmark In combination with rituximab for pts with high-risk CLL
Aug 2014 - Aug 2014: In combination with rituximab for pts with high-risk CLL
Checkmark For rituximab combination trial for high risk chronic lymphocytic leukemia
Dec 2013 - Dec 2013: For rituximab combination trial for high risk chronic lymphocytic leukemia
Checkmark ASH 2012 (Ibrutinib+Rituxan)
More
Completed
2
40
US
Rituximab, Rituxan, PCI-32765
M.D. Anderson Cancer Center, Pharmacyclics LLC.
Leukemia
08/18
08/18
NCT03145480: Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients

Terminated
2
3
US
Obinutuzumab, gazyva, Ibrutinib, imbruvica, CHOP, CHOP Regimen
Northwell Health, Pharmacyclics LLC.
Richter Syndrome
09/18
09/18
2018-001777-25: A Phase II Pilot Study to Evaluate the Safety and Efficacy of the association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction. IDA53 trial

Completed
2
44
Europe
Concentrate for solution for injection/infusion, Capsule, DARZALEX, IMBRUVICA
FILO, JANSSEN
Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction., Relapsed/Refractory Chronic Lymphocytic Leukemia with p53 dysfunction., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02902965 / 2015-005105-36: Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

Checkmark iMMPACT trial data (ibrutinib + Velcade in r/r MM)
Mar 2020 - Mar 2020: iMMPACT trial data (ibrutinib + Velcade in r/r MM)
Completed
2
74
Europe, RoW
Ibrutinib, Imbruvica, Bortezomib, Velcade, Dexamethasone
Pharmacyclics Switzerland GmbH, Janssen Research & Development, LLC
Multiple Myeloma
10/18
10/18
NCT03149315: Inhibition of Anaphylaxis by Ibrutinib

Completed
2
6
US
Ibrutinib, Ibruvica
Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine
Food Allergy, Anaphylaxis Food
11/18
11/18
IRiC study: Ibrutinib R-mini-CHOP in elderly DLBCL, ACTRN12615000551594: A Phase II Study of Ibrutinib, Rituximab and mini-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy in very elderly patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
2
80
 
Australasian Leukaemia and Lymphoma Group, Janssen-Cilag Pty Ltd
elderly DLBCL
 
 
2017-005137-23: Ibrutinib in combination to rituximab-CHOP followed by ibrutinib maintenance in untreated patients with (ABC) DLBCLat intermediate-high and high risk Terapia R-CHOP in combinazione con ibrutinib e successivo mantenimento con ibrutinib in pazienti non trattati con linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto.

Not yet recruiting
2
90
Europe
Ibrutinib, IMP1, Capsule, hard, IMBRUVICA - 140 MG -CAPSULE RIGIDE -USO ORALE - FLACONE (HDPE) - 1 FLACONE (120 CAPSULE RIGIDE)
FONDAZIONE ITALIANA LINFOMI ONLUS, Janssen-Cilag S.p.A
Activated-B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk (IPI =2) Linfoma diffuso a grandi cellule B con profilo ABC (Activated-B-Cell) e rischio intermedio/alto o alto (IPI = 2), B-Cell Lymphoma (ABC)-DLBCLat intermediate-high and high risk Linfoma diffuso a grandi cellule B con profilo ABC e rischio intermedio/alto o alto, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT02575300: Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Completed
2
20
US
Ibrutinib, IMBRUVICA®
H. Lee Moffitt Cancer Center and Research Institute, Pharmacyclics LLC.
Carcinoid Tumors, Pancreatic NET
03/19
11/19
NCT01109069: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia

Completed
2
199
US
PCI-32765
Pharmacyclics LLC., Janssen Research & Development, LLC
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Well-differentiated Lymphocytic Lymphoma, B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom Macroglobulinemia, Burkitt Lymphoma, B-Cell Diffuse Lymphoma
04/19
04/19
NCT02943473: Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients

Terminated
2
9
US
Ibrutinib, IMBRUVICA
Icahn School of Medicine at Mount Sinai, Pharmacyclics LLC.
High Risk Smoldering Multiple Myeloma
09/19
09/19
NCT02514083: A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

Active, not recruiting
2
29
US
Ibrutinib, Imbruvica, Fludarabine, Fludara
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/19
10/34
GELTAMO-IMCL-2015, NCT02682641 / 2015-004158-17: Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Active, not recruiting
2
50
Europe
IBRUTINIB, Imbruvica, Rituximab
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.
Mantle Cell Lymphoma
12/19
12/24
NCT02950038: Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

Withdrawn
2
0
NA
Ibrutinib, PCI-32765, Imbruvica, Nivolumab, BMS-936558, Opdivo
M.D. Anderson Cancer Center, Janssen Scientific Affairs, LLC
Lung Cancer, Nonsmall Cell, Stage I
12/19
 
ISRAEL, NCT03827603: Ibrutinib in Steroid Refractory Autoimmune Hemolytic Anemia

Unknown status
2
50
RoW
Ibrutinib, Imbruvica
Eugene Nikitin
AIHA - Warm Autoimmune Hemolytic Anemia
12/19
03/22
PHILEMON, NCT02460276 / 2013-005541-36: A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed
2
50
Europe
Lenalidomide, Ibrutinib, Rituximab
Lund University Hospital, Celgene, Janssen, LP, Nordic Lymphoma Group
Relapsed/Refractory Mantle Cell Lymphoma
12/19
12/19
2018-002364-44: Clinical study of ibrutinib and rituximab in untreated marginal zone lymphomas

Ongoing
2
175
Europe
MabThera Uso sottocutaneo, MabThera, Imbruvica, [NA], Solution for injection, Concentrate for solution for infusion, Capsule, hard, MabThera, Imbruvica
IELSG - INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP, Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV
Previously untreated and symptomatic patients with histologically proven CD20-positive marginal zone B-cell lymphoma (MZL) in need of systemic treatment, Previously untreated marginal zone lymphoma, Diseases [C] - Cancer [C04]
 
 
NCT03045328: Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL

Completed
2
22
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Steven E. Coutre
Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
05/20
08/21
2015-003128-30: Ibrutinib in relapsed lymphocyte-predominant Hodgkin lymphoma Ibrutinib zur Behandlung des rezidivierten nodulär Lymphozyten-prädominanten Hodgkin Lymphom

Not yet recruiting
2
36
Europe
Capsule, hard, Imbruvica
University of Cologne, JANSSEN-CILAG GmbH
relapsed lymphocyte-predominant Hodgkin lymphoma rezidiviertes nodulär Lymphozyten-prädominantes Hodgkin Lymphom, relapsed Hodgkin lymphoma (cancer of lymphatic system) Rückfall eines Hodgkin Lymphoms (Krebserkrankung des lymphatischen Systems), Diseases [C] - Cancer [C04]
 
 
NCT02670616: Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma

Completed
2
24
RoW
Ibrutinib, Imbruvica, Rituximab, Mabthera, Cyclophosphamide, Endoxan, Doxorubicin, Adriamycin, vincristine, Prednisolone, solondo
Samsung Medical Center
Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma
06/20
10/20
NCT02747732: Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

Unknown status
2
72
RoW
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6, Rituximab 375 mg/m2 IV Day 1, Cycles 1-6;, Ibrutinib, 560 mg orally, once daily
Meirav Kedmi MD, Johnson & Johnson
Diffuse Large B Cell Lymphoma, Primary Mediastinal (Thymic) Large B-cell Lymphoma, Transformed Indolent Lymphoma, Recurrent Disease, Refractory Cancer
06/20
10/21
2019-003632-23: Lenalidomide and Ibrutinib in association with R-MPV first-line treatment of Primary Central Nervous System Lymphoma for patients aged 18 to 60 Lénalidomide et Ibrutinib en association avec le R-MPV en traitement d’induction de première ligne pour les patients âgés de 18 à 60 ans présentant un lymphome primitif du système nerveux central (LCP).

Not yet recruiting
2
128
Europe
Ibrutinib 140 mg, Rituximab, Methotrexate, Procarbazine, Vincristine, Prednisone, Capsule, hard, Solution for infusion, Capsule, Tablet, Revlimid 5 mg, Revlimid 10 mg, Imbruvica 140 mg
Institut Curie, PHRC-K 2018 Public Health Grant, CELGENE SAS, JANSSEN-CILAG, KEOCYT SAS
Primary Central Nervous System Lymphoma (PCNSL) in patients aged 18 to 60, in first-line treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, en traitement de première ligne, Primary Central Nervous System Lymphoma in patients aged 18 to 60, first treatment Lymphome primitif du système nerveux central chez des patients âgés de 18 à 60 ans, 1er traitement, Diseases [C] - Cancer [C04]
 
 
NCT03093831: Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Terminated
2
5
RoW
Ibrutinib, PCI-32765, Imbruvica
National Cancer Centre, Singapore, Singapore General Hospital, Samsung Medical Center
Lymphoma, B-Cell, Marginal Zone
07/20
07/20
2019-004948-30: A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Not yet recruiting
2
200
Europe
parsaclisib 20 mg Tablets, parsaclisib 5 mg Tablets, parsaclisib 2.5 mg Tablets, parsaclisib 1 mg Tablets, INCB050465 20 mg Tablets, INCB050465 5 mg Tablets, INCB050465 2.5 mg Tablets, INCB050465 1 mg Tablets, Tablet, IMBRUVICA 140 mg hard capsules
Incyte Corporation, INCYTE CORPORATION, Incyte Corporation
Advanced malignancies, Advanced malignancies, Diseases [C] - Cancer [C04]
 
 
IRENO, NCT02626884 / 2015-003128-30: Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)

Completed
2
14
Europe
Ibrutinib
University of Cologne, JANSSEN-CILAG GmbH
Nodular Lymphocyte-Predominant Hodgkin's Lymphoma
08/20
08/20
IBDCL-GELTAMO-2015, NCT02692248 / 2015-005390-21: Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Completed
2
64
Europe
Ibrutinib, Rituximab, Gemcitabine, Oxaliplatin, Dexamethasone
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea, Janssen-Cilag, S.A.
Diffuse Large B-Cell Lymphoma
11/18
01/21
NCT03679624: Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

Terminated
2
1
US
Ibrutinib, IMBRUVICA, Daratumumab, DARZALEX
Weill Medical College of Cornell University, Janssen Scientific Affairs, LLC, Mayo Clinic
Waldenstrom Macroglobulinemia, Waldenstrom's Disease, Waldenström; Hypergammaglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia of Lymph Nodes, Waldenstrom's Macroglobulinaemia, Without Mention of Remission, Waldenstrom's Macroglobulinemia Refractory
09/20
10/20
ACE-CL-208, NCT02717611 / 2015-005317-68: A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Hourglass Dec 2025 - Dec 2025 : Data for 1L MCL
Active, not recruiting
2
60
Europe, US, RoW
ACP-196 (acalabrutinib), Acalabrutinib
Acerta Pharma BV
Chronic Lymphocytic Leukemia
10/20
06/26
CAPTIVATE, NCT02910583 / 2016-002293-12: Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

Checkmark New data from the P2 CAPTIVATE study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P2 CAPTIVATE study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark CHMP positive opinion in a fixed-duration combination regimen venetoclax for adult patients with 1L CLL
Jun 2022 - Jun 2022: CHMP positive opinion in a fixed-duration combination regimen venetoclax for adult patients with 1L CLL
Checkmark Data from CAPTIVATE trial in combination with Venclexta for CLL at ASH 2021
More
Completed
2
323
Europe, US, RoW
ibrutinib, venetoclax, Placebo
Pharmacyclics LLC., Janssen Research & Development, LLC
Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
11/20
03/24
AIM Study, NCT02471391: ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Checkmark In combination with ibrutinib in poor-prognosis mantle cell lymphoma
Mar 2018 - Mar 2018: In combination with ibrutinib in poor-prognosis mantle cell lymphoma
Checkmark Preliminary results from AIM trial of Imbruvica + Venclexta in MCL
Jun 2016 - Jun 2016: Preliminary results from AIM trial of Imbruvica + Venclexta in MCL
Active, not recruiting
2
37
RoW
ABT-199, Ibrutinib
Peter MacCallum Cancer Centre, Australia
Mantle Cell Lymphoma
11/20
06/25
NCT03755947: Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

Completed
2
3
RoW
Ibrutinib, Imbruvica, Obinutuzumab, Gazyva, Venetoclax, Venclexta
Grupo Cooperativo de Hemopatías Malignas
B-Cell Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia in Relapse (Diagnosis)
12/20
02/21
NCT04209621: Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Terminated
2
3
US
Duvelisib, Copiktra, Ibrutinib, Imbruvica
National Heart, Lung, and Blood Institute (NHLBI)
Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL)
01/21
01/21
NCT03949062: Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL

Active, not recruiting
2
30
RoW
Ibrutinib, Imbruvica, Lenalidomide, Relvimid, Rituximab, Rituxan
Ruijin Hospital
Diffuse Large B Cell Lymphoma
03/21
05/22
NCT02744612: Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed
2
39
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/21
07/24
NCT03267186: Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

Completed
2
8
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis
Andrew Rezvani, National Institutes of Health (NIH), Pharmacyclics LLC.
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic Cell Transplantation Recipient
04/21
04/21
NCT02232386 / 2014-002714-23: Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia

Completed
2
156
Europe
Ibrutinib, Rituximab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocyte Leukemia, Adult Patients
04/18
04/24
NCT04375397: Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Completed
2
46
US
Ibrutinib, Imbruvica, Placebo
AbbVie, Janssen Research & Development LLC; Pharmacyclics LLC (An AbbVie Company)
CoronaVirus Induced Disease-2019 (COVID-19)
05/21
06/21
2020-004910-37: Study to compare the efficacy and safety of the combinaison of venetoclax+ibrutinib in patients with untreated mantle cell lymphoma

Not yet recruiting
2
194
Europe
ibrutinib, venetoclax, ABT - 199, Capsule, hard, Tablet, Imbruvica, Venclyxto
LYSARC, Janssen Pharmaceutica NV, Abbvie Inc
Untreated mantle cell lymphoma, Untreated mantle cell lymphoma, Diseases [C] - Cancer [C04]
 
 
2020-004409-30: Treatment with venetoclax consolidated with ibrutinib and rituximab to increase the possibility of minimal residual disease in patient with chronic lymphotic leukemia Trattamento con venetoclax consolidato con ibrutinib e rituximab per aumentare possibilità di malattia minima residua in paziente con leucemia linfatica cronica

Not yet recruiting
2
55
Europe
venclyxto, [venclyxto], Modified-release tablet, Venclyxto
OSPEDALE SAN RAFFAELE, AbbVie
Previously Untreated Chronic Lymphophatic Leukaemia Leucemia Linfatica Cronica non precedentemente trattata, Previously untreated low-risk blood cancer Tumore del sangue a basso rischio, non precedentemente trattato, Diseases [C] - Cancer [C04]
 
 
NCT02736617: Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma

Completed
2
10
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759
OHSU Knight Cancer Institute, Genentech, Inc., Oregon Health and Science University
Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
06/21
06/21
2021-000311-23: Ibrutinib and Obinutuzumab as first-line treatment for patients with Chronic Lymphocytic Leukemia Ibrutinib e Obinutuzumab come trattamento di prima linea per pazienti affetti dalla Leucemia Linfatica Cronica

Not yet recruiting
2
53
Europe
NA, Gazyvaro, [NA], [Gazyvaro], Capsule, hard, Concentrate for solution for injection, imbruvica, gazyvaro
OSPEDALE SAN RAFFAELE, Janssen-Cilag International N.V., Belgium
chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, chronic lymphocytic leukemia/small lymphocytic lymphoma Leucemia Linfatica Cronica/ Linfoma linfocitico a piccole cellule, Diseases [C] - Cancer [C04]
 
 
Vision HO141, NCT03226301: A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Active, not recruiting
2
230
Europe
Ibrutinib + Venetoclax 15 cycles, Ibrutinib until progression/relapse, Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles
Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group
Chronic Lymphocytic Leukemia in Relapse, Chronic Lymphocytic Leukemia in Remission
06/21
06/26
NCT03232307: Ibrutinib Plus Rituximab and Lenalidomide in Treating Elderly Participants With Newly Diagnosed Mantle Cell Lymphoma

Withdrawn
2
0
NA
Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
CCND1 Positive, CD20-Positive Neoplastic Cells Present, Mantle Cell Lymphoma
07/21
07/21
NCT04025593: Biomarker Guided Treatment in DLBCL

Recruiting
2
128
RoW
Cyclophosphamide, Rituximab, Doxorubicin, Vincristine, Prednisone, Ibrutinib, Lenalidomide, chidamide, decitabine
Ruijin Hospital
Diffuse Large B Cell Lymphoma
07/21
06/23
NCT03943342: Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

Withdrawn
2
0
NA
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta
Kerry Rogers, Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Loss of Chromosome 17p
07/21
07/21
MC1485, NCT02332980: Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Checkmark In relapsed/refractory CLL at ASH 2015
Dec 2015 - Dec 2015: In relapsed/refractory CLL at ASH 2015
Checkmark ASH 2015
Nov 2015 - Nov 2015: ASH 2015
Completed
2
65
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Idelalisib, CAL-101, GS 1101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Mayo Clinic, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Richter Syndrome, Waldenstrom Macroglobulinemia
08/21
01/22
NCT04062448: A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Completed
2
16
Japan
Ibrutinib, PCI-32765, Rituximab
Janssen Pharmaceutical K.K.
Waldenstrom Macroglobulinemia
08/21
03/23
NCT04066920: IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL

Not yet recruiting
2
30
RoW
IBER salvage chemotherapy followed by ibrutinib maintenance therapy
Deok-Hwan Yang
Primary Central Nervous System Lymphoma
09/21
09/23
NCT03873493 / 2018-002179-17: A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-cell Prolymphocytic Leukemia

Completed
2
14
Europe, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta®, Venclyxto®, Ibrutinib, Imbruvica®
AbbVie
Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer
11/21
11/21
NCT02869633: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant

Completed
2
23
US
Ibrutinib, Laboratory Biomarker Analysis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
11/21
10/23
NCT04665115: Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19)

Withdrawn
2
0
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Quality-of-Life Assessment, Quality of Life Assessment
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Neoplasm, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Symptomatic COVID-19 Infection Laboratory-Confirmed, Waldenstrom Macroglobulinemia
11/21
07/22
NCT02242097: Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting
2
37
US
ibrutinib, Bruton's tyrosine kinase inhibitor PCI-32765, BTK inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, laboratory biomarker analysis
Northwestern University, Janssen Scientific Affairs, LLC, National Cancer Institute (NCI)
Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
01/23
01/25
NCT02884453: Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma

Unknown status
2
17
Europe
ibrutinib, JNJ-54179060, IMBRUVICA, PCI-32765
Royal Marsden NHS Foundation Trust, Janssen, LP
Gastrooesophageal Cancer
12/21
12/21
CLL2-GiVe, NCT02758665 / 2015-004606-41: Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL

Checkmark From CLL2GIVe trial in combination with Imbruvica & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Jun 2020 - Jun 2020: From CLL2GIVe trial in combination with Imbruvica & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Checkmark From CLL2GIVe trial in combination with venetoclax & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Jun 2020 - Jun 2020: From CLL2GIVe trial in combination with venetoclax & obinutuzumab for 1L CLL with 17p deletion and/or TP53 mutation
Completed
2
41
Europe
ibrutinib, obinutuzumab, venetoclax
University of Ulm, German CLL Study Group, Roche Pharma AG, Janssen-Cilag Ltd., AbbVie
Leukemia, Lymphocytic, Chronic
01/22
03/22
ChiCTR1900027811: Ibubutinib, Rituximab and Methotrexate in Newly-dignosed Primary Central Nervous System Lymphoma (PCNSL)

Not yet recruiting
2
31
 
Ibrutinib + Rituximab + Methotrexate
Xuan Wu Hospital, Capital Medical University; Xuan Wu Hospital, Capital Medical University, Self-raising
primary central nervous system lymphoma
 
 
NCT02662296: Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Withdrawn
2
0
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, PCI-32765, Idelalisib, CAL-101, GS-1101, Phosphoinositide-3 Kinase Delta Inhibitor CAL-101, Zydelig
Fred Hutchinson Cancer Center, National Cancer Institute (NCI)
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
02/22
 
NCT04477486: Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma

Completed
2
13
Japan
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclexta, GDC-0199, Venclyxto
AbbVie
Mantle Cell Lymphoma (MCL)
02/22
05/25
NCT03121534: Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Terminated
2
9
US
Blinatumomab, BLINCYTO®, Dexamethasone, Decadron, Ibrutinib, Imbruvica™, Nivolumab, Opdivo
M.D. Anderson Cancer Center, Amgen
Hematopoietic/Lymphoid Cancer, Richter's Transformation
02/22
02/22
NCT02420912: Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Completed
2
37
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Loss of Chromosome 17p, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Richter Syndrome
02/22
02/22
NCT02689869 / 2014-005164-15: Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma

Active, not recruiting
2
98
Europe
Ibrutinib, Imbruvica, GA 101, Obinutuzumab
Ludwig-Maximilians - University of Munich, Hoffmann-La Roche, Janssen-Cilag G.m.b.H
Indolent Non-Hodgkin Lymphoma
04/22
07/22
NCT03130348: Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

Withdrawn
2
0
NA
Bortezomib, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, LDP 341, MLN341, PS-341, PS341, Velcade, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Fluorodelta, Fortecortin, Gammacorten, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, Visumetazone, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Laboratory Biomarker Analysis
Mayo Clinic, National Cancer Institute (NCI)
Amyloidosis, Immunoglobulin Light Chain Deposition
04/22
04/22
NCT04994626: Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Not yet recruiting
2
20
NA
Ibrutinib Combined With Rituximab, Imbruvica Combined With Rituximab
Chinese Academy of Medical Sciences
DLBCL, MYD88 Gene Mutation, CD79A Gene Mutation, CD79B Gene Mutation, Relapse, Refractory Lymphoma
04/22
07/25
 

Download Options